To evaluate the efficacy and tolerability of antipsychotic medications for the management of child and adolescent onset psychosis.
Study selection Study designs of evaluations included in the review
All types of study were eligible for inclusion in the review. The included studies were randomised controlled trials (RCTs), open-label trials, retrospective chart reviews and case reports. The duration of the studies ranged from 25 days to 36 weeks.
Specific interventions included in the review
Interventions were antipsychotic drugs used in the treatment of patients aged 18 years or younger. The included studies assessed the use of the following drugs: haloperidol (16 plus or minus 8 mg/day), clozapine (from 176 plus or minus 149 mg/day, to 325 mg/day), risperidone (0.25 to 10 mg/day), olanzapine (2.5 to 10 mg/day) and quetiapine (25 to 400 mg/day).
Participants included in the review
The stated participants were child and adolescents patients with psychosis, aged 18 years or younger. The studies included a variety of age bands, one of which included patients aged up to 22 years.
Outcomes assessed in the review
Studies were included if they provided some assessment of the safety and efficacy of antipsychotics in the treatment of psychosis in this patient population. Reports of antipsychotic efficacy or adverse events in patients with nonpsychotic diagnoses were excluded.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the reviewers performed the selection.
Assessment of study quality
No formal assessment of validity was undertaken.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the reviewers performed the data extraction.
The data presented for each study included details of the participants, study design, drug dosage, clinical efficacy, and notable adverse effects.
